Tigermed Reports 2024 Interim Results
HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
Tigermed Reports Full Year 2023 Results
HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...
Tigermed Reports 2023 Interim Results
HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
Tigermed Reports Full Year 2022 Results
HANGZHOU, China, March 28, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...
Tigermed Completes Acquisition of Marti Farm
HANGZHOU, China and ZAGREB, Croatia, Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, announced today the completion of its acquisition of Marti F...
Tigermed Reports 2022 Interim Result with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its interi...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 25, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange. The issue price isCNY 18...
Qiming's Portfolio Company InventisBio Lists on STAR Market
SHANGHAI, July 24, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company InventisBio (SHSE: 688382), a leading company in innovative drug development, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.The issue price is CNY 18...
Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion
SHANGHAI, July 11, 2022 /PRNewswire/ -- Qiming Venture Partners announced today the closing of its latest funds totalingUS$3.2 billion, including USD Fund VIII atUS$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million). As in prior funds, Fund VIII was oversub...
Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List
SHANGHAI, April 13, 2022 /PRNewswire/ – Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists. Nisa Leung, Managing Partner of Qiming Venture Partners, andDuane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list. Since ...
Tigermed Reports Strong 2021 Full-Year Results
HANGZHOU, China, March 28, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...
Tigermed Recognized with Frost & Sullivan 2021 China Clinical CRO Competitive Strategy Leadership Award
HANGZHOU, China, Nov. 29, 2021 /PRNewswire/ -- Tigermed, a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, announced that it has been awarded the Frost & Sullivan 2021 China Contract Research Organization (CRO) Competitive Strategy Lea...
Tigermed Reports 2021 Interim Results with Strong Financial Growth
HANGZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its interim results for the six months endedJune 30, 202...
Tigermed Reports 2020 Annual Results With Solid Growth
HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization
HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...
